Unknown

Dataset Information

0

Treatment With Lopinavir/Ritonavir or Interferon-?1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset.


ABSTRACT: Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe disease in human with an overall case-fatality rate of >35%. Effective antivirals are crucial for improving the clinical outcome of MERS. Although a number of repurposed drugs, convalescent-phase plasma, antiviral peptides, and neutralizing antibodies exhibit anti-MERS-CoV activity in vitro, most are not readily available or have not been evaluated in nonhuman primates. We assessed 3 repurposed drugs with potent in vitro anti-MERS-CoV activity (mycophenolate mofetil [MMF], lopinavir/ritonavir, and interferon-?1b) in common marmosets with severe disease resembling MERS in humans. The lopinavir/ritonavir-treated and interferon-?1b-treated animals had better outcome than the untreated animals, with improved clinical (mean clinical scores ?50.9%-95.0% and ?weight loss than the untreated animals), radiological (minimal pulmonary infiltrates), and pathological (mild bronchointerstitial pneumonia) findings, and lower mean viral loads in necropsied lung (?0.59-1.06 log10 copies/glyceraldehyde 3-phosphate dehydrogenase [GAPDH]; P < .050) and extrapulmonary (?0.11-1.29 log10 copies/GAPDH; P < .050 in kidney) tissues. In contrast, all MMF-treated animals developed severe and/or fatal disease with higher mean viral loads (?0.15-0.54 log10 copies/GAPDH) than the untreated animals. The mortality rate at 36 hours postinoculation was 67% (untreated and MMF-treated) versus 0-33% (lopinavir/ritonavir-treated and interferon-?1b-treated). Lopinavir/ritonavir and interferon-?1b alone or in combination should be evaluated in clinical trials. MMF alone may worsen MERS and should not be used.

SUBMITTER: Chan JF 

PROVIDER: S-EPMC7107395 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset.

Chan Jasper Fuk-Woo JF   Yao Yanfeng Y   Yeung Man-Lung ML   Deng Wei W   Bao Linlin L   Jia Lilong L   Li Fengdi F   Xiao Chong C   Gao Hong H   Yu Pin P   Cai Jian-Piao JP   Chu Hin H   Zhou Jie J   Chen Honglin H   Qin Chuan C   Yuen Kwok-Yung KY  

The Journal of infectious diseases 20150721 12


Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe disease in human with an overall case-fatality rate of >35%. Effective antivirals are crucial for improving the clinical outcome of MERS. Although a number of repurposed drugs, convalescent-phase plasma, antiviral peptides, and neutralizing antibodies exhibit anti-MERS-CoV activity in vitro, most are not readily available or have not been evaluated in nonhuman primates. We assessed 3 repurposed drugs with potent in vitro anti-  ...[more]

Similar Datasets

| S-EPMC6954302 | biostudies-literature
| S-EPMC9298346 | biostudies-literature
| S-EPMC5791210 | biostudies-literature
| S-EPMC6942374 | biostudies-literature
| S-EPMC6336882 | biostudies-literature
| S-EPMC4140844 | biostudies-literature
| S-EPMC4138798 | biostudies-literature
| S-EPMC7164679 | biostudies-literature
| S-EPMC7113761 | biostudies-literature